Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.

Abstract: The invention discloses a promoter which can be induced to express in acidic conditions, and relates to the field of bioengineering technology. The promoters of the invention are separated from A. niger and can actuate and/or regulate the expression of the effectively connected nucleic acids in A. niger. In the invention the expression of the promoters is studied in A. niger, and it is indicated that some promoters show weak expression, and some show strong activity. The invention provides an effective method and new thought for organic acids production by fungi or other products produced by fermentation under acidic conditions.

Abstract: The present invention relates to a mutant Brassica plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin. The mutant Brassica plant has a reduced level, reduced activity or complete absence of DMR6-1 protein and DMR6-2 protein as compared to a wild type Brassica plant.

Abstract: The present invention relates to crop breeding. More particularly, the present invention relates to targeted modification of root to enhance abiotic stress tolerance in maize. In one aspect, the invention provides recombinant maize exhibiting increased root angle. Methods of making the recombinant maize and various methods of plant selection and breeding are further provided.

Abstract: The invention provides combining certain genetic mutations in plants to increase sugar levels in the vegetative tissues of the plants. The specific combinations of mutations yield increased oil production in the vegetative tissues. In one embodiment, a plant comprises two mutations, wherein the two mutations are an adg1 mutation and a suc2 mutation. In one embodiment, a plant comprises three mutations, wherein the three mutations are an adg1 mutation, a suc2 mutation and a sdp1 mutation, or comprises an adg1 mutation, a suc2 mutation and a tt4 mutation. In one embodiment, the plant comprises four mutations, wherein the four mutations are an adg1 mutation, a suc2 mutation, an sdp1 mutation, and a tgd1 mutation, or comprises an adg1 mutation, a suc2 mutation, a tt4 mutation and a tgd1 mutation.

Abstract: Isolated polynucleotides and polypeptides, and recombinant DNA constructs useful for conferring improved nitrogen use efficiency and/or drought stress tolerance; compositions (such as plants or seeds) comprising these recombinant DNA constructs; and methods utilizing these recombinant DNA constructs are disclosed. The recombinant DNA constructs comprise a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotides encode abiotic stress tolerance polypeptides.

Abstract: Provided are a glyphosate-resistant gene screening method, an EPSPS mutant gene having glyphosate resistance screened by the method, an EPSPS and C-P Lyase deficient strain and a use thereof.

Abstract: Described are DNA molecules which can be transcribed into an mRNA harbouring novel UTR sequences combining the advantages of being extremely short and at the same time allowing for high translation efficiencies of RNA molecules containing them. Further, described are vectors comprising such a DNA molecule and to host cells comprising such a vector. Moreover, described are corresponding RNA molecules containing such UTRs. Further, described in a pharmaceutical composition comprising the described RNA molecule are optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.

Abstract: rAAV compositions useful for preventing the toxicity associated with organophosphate exposure are provided herein. The rAAV co-express a human butyrylcholinesterase and a proline-rich peptide. Each the esterase and the peptide may have an exogenous signal sequence. Also provided are compositions, e.g., aqueous liquid suspensions containing the rAAV.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: The present invention provides the use of a nucleic acid encoding SOCS1 for enhancing the efficacy of introducing at least one nucleic acid of interest into a cell; a method of repeated transfection of a cell with at least one nucleic acid of interest comprising the steps of adding a) nucleic acid encoding SOCS1, and simultaneously or subsequently b) at least one nucleic acid of interest encoding at least one polypeptide of interest, wherein at least step b) is repeated at least once; and a method of electroporation of a cell with at least one nucleic acid of interest comprising the steps of adding to the cell a) a nucleic acid encoding SOCS1, and simultaneously or subsequently b) said at least one nucleic of interest. The at least one nucleic acid of interest and the nucleic acid encoding SOCS1 may be mRNAs, wherein each of said mRNAs has a poly(A) tail at its 3? end comprising at least 200 adenines.

Abstract: Provided herein are compositions and methods of integrating one or more exogenous donor nucleic acids into one or more exogenous landing pads engineered into a host cell's genome. In certain embodiments, the exogenous landing pads and exogenous donor nucleic acids comprise standardized, compatible homology regions so that exogenous donor nucleic acids can integrate into any of the landing pads, independent of the genomic sequences surrounding the landing pads. In certain embodiments, the methods comprise contacting the host cell comprising landing pads with one or more exogenous donor nucleic acids, and a nuclease capable of causing a double-strand break within the landing pads, and recovering a host cell comprising one or more exogenous donor nucleic acids integrated in any of the landing pads.

Abstract: Provided herein are CRISPR/Cas9 complexes and method of using same.

Abstract: The present application relates to the field of glyco-engineering, more specifically to glycosylation-engineered fungal cells, more specifically glycosylation-engineered yeast cells, optimized to produce highly homogenous forms of complex N-glycans on recombinant proteins. The invention specifically relates to methods to obtain pharmaceutical compositions comprising recombinant glycoproteins which have homogenous forms of complex N-glycans. In addition, the invention relates to novel pharmaceutical compositions which result from the methods of the invention.

Abstract: The present disclosure is related to a process comprising steps of fermentation, separation and purification that can be carried out in a centralized facility with large scale fermentation or in a decentralized facility with smaller scales of fermentation to make value added products from substrate not limiting to gaseous substrates effectively. The fermentation involves fermentative production of a marketable product using reactors or fermentors which are optimized for influential parameters such as gaseous substrate, gas hold up, mass transfer coefficient, etc. The separation step involves an effective way of separating desired product from fermentation broth by employing filtration, precipitation or adsorption techniques thereby enabling easy transportation of the product in case of a decentralized facility. The final stage of the process, either in centralized or decentralized facility, includes the elution of retained product and further purification of the same using downstream processing techniques.

Abstract: Engineered microorganisms are provided that convert gaseous substrates, such as producer gas, into limonene. In some embodiments, limonene is pumped out of the cell via an efflux pump. In some embodiments, limonene, produced as described herein, is converted through catalytic dimerization into jet fuel. Producer gas used in the processes described herein for production of limonene may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Integrated mixotrophic fermentation method comprising (i) an isolated naturally acetogenic organism; (ii) a first feedstock comprising a carbon source for use in a fermentation medium; (iii) a second feedstock comprising elemental hydrogen for use in the fermentation medium; wherein the second feedstock comprises performing electrolysis; and (iv) culturing the organism in the fermentation medium, whereby both feedstocks are metabolized and a fermentation broth is formed, which broth comprises at least one bioproduct.

Abstract: A method of obtaining useful material from plant biomass waste. The method uses sonication and/or microwave irradiation followed by sequential incubation with mixed fungal cultures. In particular, the method involves obtaining useful material from plant biomass waste comprising the steps of: a) subjecting the biomass waste to microwave irradiation and/or sonication; b) incubating the biomass waste from step a) with one or more enzymes extracted from Basidiomycete fungi; and c) incubating the biomass waste from step b) with one or more enzymes extracted from Ascomycete fungi.

Abstract: Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy or sugary materials, to produce ethanol and/or butanol, e.g., by fermentation.

Abstract: A process for forming a fuel or a fuel intermediate using three fermentations includes treating a feedstock to obtain a fermentable carbohydrate, conducting a first fermentation to ferment the fermentable carbohydrate to fermentation product, obtaining biogas produced from a second fermentation that includes anaerobic digestion, and conducting a third fermentation to ferment a gas to produce fermentation product, where the gas contains one or more components obtained or derived from the biogas. An aqueous stream containing fermentation product produced in the third fermentation is used within the process.

Abstract: A process is provided for forming a fuel or a fuel intermediate from two fermentations that includes feeding an aqueous solution comprising a fermentation product from a first bioreactor to a second bioreactor and/or a stage upstream of the second bioreactor, which also produces the fermentation product. The aqueous solution may be added at any stage of the second fermentation and/or processing steps upstream from the second bioreactor that would otherwise require the addition of water. Accordingly, the product yield is increased while fresh/treated water usage is decreased.

Abstract: Recombinant microbial cells comprising an engineered LCDA production pathway that comprises at least one up-regulated long-chain acyl-CoA synthetase (ACoS) are disclosed. These recombinant microbial cells are capable of producing one or more long-chain dicarboxylic acid (LCDA) products from a long-chain fatty acid-comprising substrate. Methods of using recombinant microbial cells to produce LCDAs are also disclosed.

Abstract: This invention describes a method of using microbial to produce fats, such as fatty acids and their derivatives, or products derived from the fatty acid synthesis cycle, such as hydroxyfatty acids, methyl ketones, and the like.

Abstract: The present invention relates to processes for the preparation of sclareolide and related compounds by the biocatalytic cyclization of polyunsaturated carboxylic acid compounds, in particular of homofarnesylic acid and related compounds; and to a process for the preparation of ambroxide via the biocatalytic cyclization of homofarnesylic acid to sclareolide.

Abstract: A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.

Abstract: The present invention relates to a novel thermophilic and thermoresistant polyphosphate-dependent glucokinase having excellent stability, a composition comprising the same, and a method for producing glucose 6-phosphate using the same.

Abstract: The present invention relates to methods of releasing galactose from legumes using polypeptides having alpha-galactosidase activity. The invention also relates to polypeptides having alpha-galactosidase activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of 5 producing the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides in animal feed.

Abstract: This invention provides a fermentation method of producing gellan gum, wherein a certain amount of fermentation broth is retained in the fermentor as a seed for next batch fermentation or transferred to another fermentor as a seed for next batch fermentation in that fermentor. The fermentation method of this invention reduces fermentation cost of gellan gum and lowers contamination risk during seed cultivation.

Abstract: Provided are a microorganism having enhanced cellulose productivity, a method of producing cellulose by using the microorganism, and a method of producing the microorganism.

Abstract: The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.

Abstract: Disclosed are methods for amplifying a nucleic acid target region using an amplification oligomer comprising a target-binding segment and a heterologous displacer tag situated 5? to the target-binding segment. Initiation of an amplification reaction from the tagged amplification oligomer produces an amplicon comprising the displacer tag, such that once the complement of the displacer tag has been incorporated into a second amplicon, a displacer oligonucleotide having a sequence substantially corresponding to the displacer tag sequence is used to participate in subsequent rounds of amplification for displacement of an extension product primed from a site within the second amplicon 5? to the displacer priming site. Also disclosed are related kits and reaction mixtures comprising the displacer-tagged amplification oligomer and corresponding displacer oligonucleotide.

Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides, glycosides of steviol precursors, and steviol glycoside precursors.

Abstract: High cell density anaerobic fermentation for protein expression. A method for producing a protein is described, including providing a modified Butyribacterium methylotrophicum (Bme) strain host; providing a fermentation medium including a carbon source and a nitrogen source; culturing the modified host in the fermentation medium under anaerobic conditions, where the carbon source is metabolized and a fermentation broth including at least one protein is formed and optionally separating the protein; where the Bme cell density in the fermentation broth is greater than 15 g/L.

Abstract: An agent capable of increasing the activity of branched-chain alpha-keto acid dehydrogenase (BCKDH) for use in increasing leptin levels. The invention also relates to the use of such agents for supporting satiety and for supporting weight maintenance and/or treating or preventing obesity.

Abstract: A device that conducts side-by-side demonstration of products helps an audience to understand the product benefits of one product over another product.

Abstract: Methods of culturing and detecting a biomarker which may be associated with autoimmune diseases, in particular inflammatory bowel disease and Crohn's disease; also a screening method for substances suitable for the treatment of inflammatory bowel disease including Crohn's disease; the method including culturing a biomarker in a culture media which includes a culture broth, OADC, PANTA and Mycobactin J.

Abstract: This invention provides purified and recombinantly-produced bacterial lipoprotein signal peptidase (Lsp) enzymes and in vitro assays for monitoring Lsp catalytic activities. Also provided in the invention are screening methods for identifying novel antibiotic agents and their therapeutic applications for treating bacterial infections. Further provided in the invention are specific Lsp inhibitory compounds which can be used as bactericidal agents in treating diseases caused by bacterial infections.

Abstract: A microfluidic chip system includes an input for receiving the biologic sample, and a first reading window for enabling a detection of the biologic material within the biologic sample. A first plurality of pathways is provided each for determining a treatment agent providing a best treatment efficacy for the predetermined biologic material. A first micro-pump is provided for pumping a portion of the biologic sample into each of the first plurality of pathways. A second plurality of pathways is provided, each for determining a dosage level of a particular one of the plurality of treatment agents with respect to the predetermined biologic material. A plurality of second micro-pumps are provided for pumping a second portion of the biologic sample into a selected one of the second plurality of pathways responsive to the determination of treatment efficacy of the treatment agent providing a best treatment of the predetermined biologic material.

Abstract: A system for testing a treatment agent for a biologic material includes an input for receiving a biologic sample. A plurality of micro-pumps pump a portion of the biologic sample from the first reservoir into a connected module. A first module includes a first plurality of testing pathways for testing a first portion of the biologic sample. A first module connector removeably connects the first module to the distributor module. A second module includes a second plurality of testing pathways for testing a second portion of the biologic sample. The selected pathway applies at least one dosage level of a treatment agent to the second portion of the biologic sample. A second module connector removeably connects the second module to the distributor module, wherein treatment agent and the plurality of dosage levels tested by the system may be selected by selecting the second module associated with the second module connector.

Abstract: A sampling device and a method for taking samples. The sampling device includes a cap having two ends and a collection sponge attached on one end, wherein a collection sponge diameter is greater than a collection sponge height. A lid is removably attached to a first end of the cap to cover the collection sponge; and a bowl is removably attached to a second and opposite end of the cap. The bowl can contain an enrichment broth.

Abstract: Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: The present invention discloses methods for identification of oligonucleotides by manipulation of the information content a plurality of oligonucleotides. A main object of the methods is the identification of new molecular activity such as new ligands of interest for the development of therapeutics or in the field of nanotechnology.

Abstract: Provided herein, are matrices and methods for the stabilization of proteins and nucleic acids. The stabilized proteins and nucleic acids described herein can be in a sample taken from a subject and can be subsequently stabilized and stored on the matrix. An analyte of interest can be concentrated and eluted for analysis from this sample. The stabilized proteins and nucleic acids described herein can be components of a sample preparation reagent, and the reagent is stored on the matrix and hydration of the matrix with a sample can result in a reaction occurring.

Abstract: Provided herein are methods and compositions for depleting targeted nucleic acid sequences from a sample, enriching for sequences of interest from a sample, and/or partitioning of sequences from a sample. The methods and compositions are applicable to biological, clinical, forensic, and environmental samples.

Abstract: A disposable test card configured to accept a fluid sample for an assay, and a method of manufacturing same, is disclosed herein. In a general example embodiment, a test card for analysing a fluid sample includes a first substrate layer including an inlet port and an outlet port, a channel layer bonded to the first substrate layer, the channel layer including a microchannel placing the inlet port in fluid communication with the outlet port, and a second substrate layer bonded to the channel layer, the second substrate layer having electrodes printed adjacent to a target zone of the microchannel of the channel layer, wherein the electrodes are configured to raise the temperature of the fluid sample within the target zone of the microchannel when a current is applied thereto.

Abstract: Using the full repertoire of genetic information from bacterial genomes and plasmids for improved genetic resistance tests The invention relates to a method of determining an antimicrobial drug resistance profile for a microorganism, wherein nucleic acid sequences of the microorganism are analyzed for at least two genetic variations of the nucleic acid sequences comprising at least one genetic variation in a chromosome and at least one genetic variation in at least one plasmid, as well as a, e.g. diagnostic, method of determining an infection of a patient with a microorganism potentially resistant to antimicrobial drug treatment and a method of selecting a treatment of a patient suffering from an infection with a potentially resistant microorganism, wherein the data of the antimicrobial drug resistance profile are applied.

Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.

Abstract: Provided are molecular entities capable of transforming, aggregating or assembling into a three dimensional biosensors.

Abstract: Embodiments of this invention are directed towards the sensitive, fast, and accurate identification and/or characterization of a single cell or bacterium, particularly phenotypic characterization. Certain aspects of the invention include assays that include functional nucleic acid probes (FNAPs). FNAPs can be used to generate deoxyribozyme cleavage cascades (DRCC) initiated by activation of a FNAP resulting in a detectable signal from a single cell.